Literature DB >> 19141308

Charles Bonnet syndrome: successful treatment of visual hallucinations due to vision loss with Yi-gan san.

Tsuyshi Miyaoka, Michiharu Nagahama, Keiko Tsuchie, Maiko Hayashida, Akira Nishida, Takuji Inagaki, Jun Horiguchi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19141308     DOI： 10.1016/j.pnpbp.2008.12.005

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN： 0278-5846            Impact factor:   5.067


× No keyword cloud information.
  8 in total

1.  Efficacy and safety of yokukansan in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled trial (a Positive and Negative Syndrome Scale, five-factor analysis).

Authors:  Tsuyoshi Miyaoka; Motohide Furuya; Jun Horiguchi; Rei Wake; Sadayuki Hashioka; Masaya Tohyama; Norio Mori; Yoshio Minabe; Masaomi Iyo; Shyuichi Ueno; Sachiko Ezoe; Kenta Murotani; Syuzo Hoshino; Haruo Seno
Journal:  Psychopharmacology (Berl)       Date:  2014-06-13       Impact factor: 4.530

2.  Eye-related visual hallucinations: consider 'Charles Bonnet syndrome'.

Authors:  Nilgun Cinar; Sevki Sahin; Sibel Karsidag
Journal:  Indian J Ophthalmol       Date:  2011 May-Jun       Impact factor: 1.848

3.  Efficacy and safety of yokukansan in treatment-resistant schizophrenia: a randomized, multicenter, double-blind, placebo-controlled trial.

Authors:  Tsuyoshi Miyaoka; Motohide Furuya; Jun Horiguchi; Rei Wake; Sadayuki Hashioka; Masaya Thoyama; Kenta Murotani; Norio Mori; Yoshio Minabe; Masaomi Iyo; Shuichi Ueno; Sachiko Ezoe; Syuzo Hoshino; Haruo Seno
Journal:  Evid Based Complement Alternat Med       Date:  2015-04-14       Impact factor: 2.629

4.  Screening for Charles Bonnet syndrome: Should the definition be reconsidered?

Authors:  PremNandhini Satgunam; Rebecca Sumalini; Gayathri Chittapu; Gunasree Pamarthi
Journal:  Indian J Ophthalmol       Date:  2019-07       Impact factor: 1.848

5.  Yokukansan improves distress of medical staff, and cognitive function and motivation in patients with destructive and aggressive behaviors after traumatic brain injury.

Authors:  Tomomichi Kan'o; Jing-Yan Han; Kuniaki Nakahara; Shingo Konno; Mayuko Shibata; Takao Kitahara; Kazui Soma
Journal:  Acute Med Surg       Date:  2014-03-05

6.  Yokukansan (TJ-54) for treatment of pervasive developmental disorder not otherwise specified and Asperger's disorder: a 12-week prospective, open-label study.

Authors:  Tsuyoshi Miyaoka; Rei Wake; Motohide Furuya; Kristian Liaury; Masa Ieda; Kazunori Kawakami; Keiko Tsuchie; Takuji Inagaki; Jun Horiguchi
Journal:  BMC Psychiatry       Date:  2012-11-29       Impact factor: 3.630

Review 7.  Yokukansan and its ingredients as possible treatment options for schizophrenia.

Authors:  Chuan-Hsun Yu; Ryouhei Ishii; Shun-Chieh Yu; Masatoshi Takeda
Journal:  Neuropsychiatr Dis Treat       Date:  2014-09-01       Impact factor: 2.570

Review 8.  Yokukan-san: a review of the evidence for use of this Kampo herbal formula in dementia and psychiatric conditions.

Authors:  Hideki Okamoto; Masaomi Iyo; Keigo Ueda; Cheolsun Han; Yoshiro Hirasaki; Takao Namiki
Journal:  Neuropsychiatr Dis Treat       Date:  2014-09-12       Impact factor: 2.570
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.